Hims & Hers Health, Inc. (HIMS)
NYSE: HIMS · Real-Time Price · USD
33.62
-2.21 (-6.17%)
At close: Nov 20, 2025, 4:00 PM EST
33.55
-0.07 (-0.21%)
After-hours: Nov 20, 2025, 7:59 PM EST
Hims & Hers Health Revenue
Hims & Hers Health had revenue of $598.98M in the quarter ending September 30, 2025, with 49.16% growth. This brings the company's revenue in the last twelve months to $2.21B, up 78.02% year-over-year. In the year 2024, Hims & Hers Health had annual revenue of $1.48B with 69.33% growth.
Revenue (ttm)
$2.21B
Revenue Growth
+78.02%
P/S Ratio
3.39
Revenue / Employee
$1,350,616
Employees
1,637
Market Cap
7.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.48B | 604.51M | 69.33% |
| Dec 31, 2023 | 872.00M | 345.08M | 65.49% |
| Dec 31, 2022 | 526.92M | 255.04M | 93.81% |
| Dec 31, 2021 | 271.88M | 123.12M | 82.77% |
| Dec 31, 2020 | 148.76M | 66.20M | 80.18% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
HIMS News
- 2 days ago - Il Makiage parent Oddity takes aim at Hims with new telehealth skincare platform Methodiq - CNBC
- 3 days ago - Ready For A Rebound? Here Are 10 Oversold Stocks To Watch - Benzinga
- 3 days ago - Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization - Business Wire
- 3 days ago - Hims & Hers names ex-FDA official Deb Autor as first policy chief - Reuters
- 3 days ago - Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy - Business Wire
- 6 days ago - Hims & Hers Introduces Labs With Annual Plans For Comprehensive Testing - Benzinga
- 7 days ago - Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks - Benzinga
- 7 days ago - Hims & Hers Introduces Labs, a Holistic, In-Depth Testing Experience That Puts Customers in Control of Their Health and Wellness Journeys - Business Wire